2026年11月2日星期一
M
寰宇通鑑
グローバル速報
Nuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei AsiaNuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei Asia

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

出典 Nature 医学研究4 日前
内容の要約

当サイトはタイトルと要約のインデックスのみを提供しています。完全なコンテンツと著作権はすべて元の配信元に帰属します。原文リンクをクリックしてご覧ください。

原文へ
所属チャンネル
健康
所属地域
グローバル視点
原文の言語
English
項目番号
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · 寰宇通鑑